Zacks Investment Research upgraded shares of Histogenics Corporation (NASDAQ:HSGX) from a hold rating to a buy rating in a research report released on Wednesday morning. Zacks Investment Research currently has $2.25 target price on the biotechnology company’s stock.

According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “

A number of other research firms have also weighed in on HSGX. Canaccord Genuity reaffirmed a buy rating and issued a $4.00 price objective on shares of Histogenics Corporation in a research note on Friday, August 11th. HC Wainwright reaffirmed a buy rating and issued a $3.50 price objective on shares of Histogenics Corporation in a research note on Thursday, November 2nd. Finally, ValuEngine lowered shares of Histogenics Corporation from a sell rating to a strong sell rating in a research note on Monday, August 14th.

Histogenics Corporation (NASDAQ:HSGX) traded up $0.06 during trading on Wednesday, hitting $1.91. 12,598 shares of the company’s stock were exchanged, compared to its average volume of 111,962. Histogenics Corporation has a 12-month low of $1.45 and a 12-month high of $2.40.

Histogenics Corporation (NASDAQ:HSGX) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. equities research analysts anticipate that Histogenics Corporation will post -1.07 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/histogenics-corporation-hsgx-upgraded-at-zacks-investment-research/1712306.html.

Histogenics Corporation Company Profile

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get a free copy of the Zacks research report on Histogenics Corporation (HSGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.